We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mallinckrodt to Settle FTC Monopoly Charges for $100 Million
Mallinckrodt to Settle FTC Monopoly Charges for $100 Million
Mallinckrodt will pay $100 million to settle FTC charges that the company maintained a U.S. monopoly for the only approved adrenocorticotropic hormone (ACTH) drug, Acthar, by acquiring the rights to a rival therapy, Synacthen.